Brief: Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

Larimar Therapeutics

23/01/2025 22:56

Jan 23 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS ANNOUNCES DOSING OF ADOLESCENTS IN
NOMLABOFUSP PEDIATRIC PHARMACOKINETIC RUN-IN STUDY FOR PATIENTS
WITH FRIEDREICH’S ATAXIA
    * LARIMAR THERAPEUTICS INC - TO INITIATE COHORT OF CHILDREN
2-11
YEARS OLD IN 1H 2025

Source text:  ID:nGNX8Tvrsz 
Further company coverage:  LRMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))